IN THE SPECIFICATION

Please insert the following formula at page 3 before paragraph [0007]:

Please replace paragraph [0007] beginning at page 3 with the following rewritten paragraph:

[0007]

However, actually, compound (B) in vitro exhibits antagonistic activity only to NK-2 receptor. When any of compounds (A) to (C) are perorally administered, satisfatory satisfactory antagonistic activity is not always attained (Patent Documents [[4]] 2 and [[5]] 4).

Please replace paragraph [0008] beginning at page 3 with the following rewritten paragraph:

[8000]

Meanwhile, the aforementioned optically active sulfoxide derivative (D) is known to exhibit excellent antagonistic activity against both NK-1 receptor and NK-2 receptor (see Patent Document 4). However, there are only a limited number of reports on low-molecular-weight compounds exhibiting antagonistic activity against NK-1 receptor or NK-2 receptor.

Patent Document 1: International Patent Publication WO94/29309 pamphlet)

Patent Document 2: International Patent Publication WO94/17045 pamphlet)

Patent Document 3: International Patent Publication WO94/26735 pamphlet)

U.S. Application No. 10/566,252 Preliminary Amendment

Patent Document 4: International Patent Publication WO94/17045 pamphlet

Patent Document [[5]] 4: Japanese Patent Application Laid-Open (kokai) No. 11-43490

Disclosure of the Invention

Problems to be Solved by the Invention

Please replace paragraph [0056] beginning at page 19 with the following rewritten paragraph:

[0056]

The "amino group which may be substituted by a phenyl group or a lower alkyl group" is a non-substituted amino group, or an amino group which has been substituted by a phenyl group or the above lower alkyl group (an amino group which has been substituted by the above lower alkyl group is referred to as "(lower alkyl)amino group"). The ring-hydrogen on phenyl may be substituted by any of the above substituents. Specific examples of the amino group which has been substituted by a phenyl group include phenylamino, N,N-diphenylamino, and tolylamino (p-methylphenylamino). Specific examples of the (lower alkyl)amino group include methylamino, dimethylamino, ethylamino, diethylamino, [[and]] n-propylamino and N-cyclohexyl-N-methylamino. Specific examples of the amino group which has been substituted by the phenyl group and the (lower alkyl)amino group include N-phenyl-N-methylamino, N-cyclohexyl-N-phenylamino, N-tolyl-N-methylamino, and N-phenyl-N-ethylamino.

U.S. Application No. 10/566,252 Preliminary Amendment

Please replace paragraph [0441] beginning at page 141 with the following rewritten paragraph:

[0440]

Similar to Example 26(h), the title compound was obtained (1.34 g, 93.4%) by use of tert-butyl {[2-(S)-(3,4-dichlorophenyl)-1-(2,2,2-trifluoro-N-methylacetamide)-4-oxo]butan-2-yl}methylcarbamate (1.0 g) synthesized in Example [[25(c)]] <u>27(c)</u> and spiro(benzo(c)thiophene-(2S)-oxido-1(3H),4'-piperidine)/(S)-(+)-mandelate (871 mg).